Send me real-time posts from this site at my email

Feb. 19 - Trading List: Updates, Analyst Actions, Our Take - VKTX

Notable updates, news, or analysts actions from our trading lists followed by 'Our Take'.

Chardan trims Viking Therapeutics target to $19 as COVID pushes out Voyage data

Chardan analyst Michael Morabito lowered the firm's price target on Viking Therapeutics to $19 from $20 and keeps a Buy rating on the shares after the company reported its Q4 results, along with which it announced that it now expects that the Phase IIb VOYAGE trial for VK2809 in NASH will complete enrollment in the second half of 2021 due to COVID-19 delays. He has pushed back his expectation for the commercial timing for VK2809 coming to market by several months, with a late 2025 or 2026 debut now "more likely," Morabito tells investors.

Our Take:  "One of our prospects with good potential in the NASH space. We would build up a position by selling puts. We will need some patience as the time frame is being extended out".

$VKTX, Viking Therapeutics, Inc. / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so)!

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.


Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue